FUJIFILM Announces Expanded Capabilities for REVORIA PRESS™ Series with New Workflow, Specialty Toners, and Finishing Solutions
'These new enhancements to our REVORIA PRESS series underscore our commitment to providing innovative and flexible solutions that help our customers thrive in a competitive market,' said Yuji Oki, general manager, FUJIFILM North America Corporation, Business Innovation Division. 'Whether it's a small shop needing an efficient workflow solution or a commercial printer looking to expand its specialty printing capabilities, these updates offer tangible benefits that drive business growth and customer satisfaction.'
Revoria XMF PressReady Lite
A direct response to market need, the Revoria XMF PressReady Lite is a customized version of Fujifilm's original XMF PressReady workflow solution that is specifically designed to add value to smaller companies, especially those that only use one or two presses for production. The simplified, cost-effective workflow solution allows print providers to automate key tasks - including full PDF preflighting, file error detection and correction - in addition to creating automated workflows that intelligently group jobs by similar media or toner needs, minimizing changeovers and maximizing efficiency, ultimately saving time and reducing human error. As a software add-on, PressReady Lite can be installed on a Revoria Flow server configured for use with Fujifilm's Revoria Press SC285, EC2100, and PC1120 models.
Silver & White Specialty Toners
To empower customers with the ability to produce more dynamic designs, Fujifilm is introducing new Silver & White specialty toners for its REVORIA PRESS EC2100S and SC285S models. Significantly broadening the creative potential and commercial appeal of digital print applications, these additions join the existing Pink, Clear, and Textured Clear options. The addition of Silver toner allows customers to produce stunning metallic effects that elevate branding for higher perceived value, making it ideal for high-end business cards, brochures, and promotional materials. White toner enables the production of vibrant, high-impact images on dark, transparent substrates, which is perfect for premium innovative marketing collateral. Together the addition of these two toners offers versatility without compromised quality, facilitates efficient workflows, allowing five-color printing in a single pass, and ultimately enables customers to differentiate in competitive markets.
Plockmatic Booklet Maker Availability for EC2100 Series
Completing the comprehensive update, the Plockmatic Booklet Maker will now be available on the Revoria Press EC2100 series. This in-line finishing solution streamlines the production of high-quality booklets, brochures, and catalogs, reducing manual post-press processes and further increasing overall productivity. The Plockmatic Booklet Maker offers seamless integration, providing a complete end-to-end solution for a wide range of applications.
Each of these solutions is now available in the North American market. For more information on Fujifilm's Business Innovation products, visit https://print-us.fujifilm.com/.
About Fujifilm
FUJIFILM North America Corporation, a marketing subsidiary of FUJIFILM Holdings America Corporation, consists of six operating divisions. The Imaging Division provides consumer and commercial photographic products and services, including silver halide consumables; inkjet consumables; digital printing equipment, along with service and support; personalized photo products fulfillment; film; one-time-use cameras; and the popular INSTAX® line of instant cameras, smartphone printers, instant film, and accessories. The Electronic Imaging Division markets its GFX System and X Series lines of mirrorless digital cameras, lenses, and accessories to provide a variety of content creation solutions for both still and moving imagery. The Optical Devices Division provides optical lenses for the broadcast, cinematography, closed circuit television, videography, and industrial markets, and also markets binoculars and other optical imaging solutions. The Business Innovation Division offers a full lineup of digital print and toner technologies focused on enabling the digital transformation of businesses and print shops with its offerings of multifunction printers, digital inkjet presses, production toner printers, software, and more. The Industrial Products Division delivers new products derived from Fujifilm technologies including data storage tape products, including OEM and FUJIFILM Ultrium LTO cartridges, desalination solutions, microfilters and gas separation membranes.
For more information, please visit https://www.fujifilm.com/us/en/about/region, go to https://x.com/fujifilmus to follow Fujifilm on X, or go to www.facebook.com/FujifilmNorthAmerica to Like Fujifilm on Facebook.
FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.
For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, click here.
FUJIFILM, REVORIA PRESS, and instax are trademarks of FUJIFILM Corporation and its affiliates.
© 2025 FUJIFILM North America Corporation and its affiliates. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
34 minutes ago
- Business Wire
Techcyte and Modella AI Announce a Research Collaboration with Modella AI's State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform
OREM, Utah--(BUSINESS WIRE)-- Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion ™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings together Modella AI's groundbreaking research-use only AI co-pilot for pathologists, PathChat ™, with Techcyte's integrated, cloud-based digital pathology platform—supporting the advancement of workflow efficiency and expanding access to advanced AI-powered pathology tools for research. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. Modella AI is a biomedical artificial intelligence company focused on improving pathology through generative and agentic AI. Its flagship research product, PathChat, enables intelligent interactions with digital slides—offering capabilities such as report summarization, image interpretation, and contextual question answering. An advanced research-use only version of the tool, PathChat DX, has been granted U.S. Food and Drug Administration Breakthrough Device Designation, reflecting the device's potential to provide a more effective diagnosis of a life-threatening or irreversibly debilitating condition. While this designation recognizes the potential of the technology, any use of PathChat within the Techcyte Fusion platform remains for research use only and is not intended for clinical diagnostic purposes. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. 'Together, our goal is delivering practical AI that pathologists can trust and that seamlessly integrates into their digital workflows.' 'We're excited to partner with Techcyte to bring our pathology-native AI to a broader research audience,' said Jill Stefanelli, President, Cofounder, and Chief Executive Officer at Modella AI. 'Integrating PathChat into the Fusion research platform supports the exploration of AI-assisted workflows in pathology and reflects our shared commitment to advancing digital innovation in the lab.' The integration of PathChat into Techcyte Fusion represents a significant step forward in operationalizing next-generation AI. As pathology workloads increase and case complexity grows, this collaboration represents an important step toward exploring AI capabilities in digital pathology research settings—all within the familiar Techcyte platform. For more information about the Techcyte Fusion Partner Program, visit About Techcyte Techcyte is aiming to transform the practice of pathology through a unified, AI-powered digital platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab. By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment. Visit for more information. Techcyte's anatomic and clinical pathology platform is for Research Use Only in the United States. About Modella Modella AI ( is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. By combining expertise in artificial intelligence and pathology, Modella AI aims to deliver innovative solutions that empower clinicians, improve patient outcomes, and transform medical workflows. Disclaimer: PathChat ™, PathChat ™ DX and the Techcyte Fusion ™ platform are research-use only devices and are not commercially available in the United States (as they are not FDA cleared or approved). The Techcyte Fusion platform is commercially available in Europe for diagnostic use. The FDA Breakthrough Device Designation for PathChat DX does not imply FDA clearance or approval. This press release contains forward-looking statements based on current assumptions and forecasts. Modella AI and Techcyte assume no obligation to update these statements to reflect future events or developments.
Business Wire
34 minutes ago
- Business Wire
Catalyst OrthoScience Announces Full Commercial Release of Fracture Shoulder System
NAPLES, Fla.--(BUSINESS WIRE)-- Catalyst OrthoScience Inc. ('Catalyst'), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announced today the full commercial release of the Catalyst Fracture Shoulder System. While this marks the latest innovation in Catalyst's expanding portfolio, the company continues to expand its momentum within the orthopedic community – underscored by recently published midterm data from its Catalyst CSR™, which demonstrates industry-leading Single-Assessment Numeric Evaluation (SANE) scores. At Catalyst, we're not bound by convention – we're defining what comes next. Our technology is designed to solve real shoulder arthroplasty challenges and we're committed to helping shoulder surgeons achieve better results with less complexity. Share 'At Catalyst, we're not bound by convention – we're defining what comes next,' said Carl O'Connell, president and chief executive officer of Catalyst. 'Our technology is designed to solve real shoulder arthroplasty challenges, and our clinical outcomes prove the value of that approach. We're committed to helping shoulder surgeons achieve better results with less complexity.' This release continues to expand Catalyst's differentiated portfolio, bringing a fracture-specific solution that prioritizes tuberosity fixation and healing—key factors consistently shown to produce better outcomes. Designed to improve reverse shoulder arthroplasty for proximal humeral fractures (PHFs), the system includes patented technology that helps reduce surgical complexity and drive clinical confidence. Entering a fracture market estimated at over $250 million, Catalyst is seeing strong early adoption and is positioned to capture significant market share. The news comes on the heels of its recent announcement of 5-8 year published midterm data supporting its Catalyst CSR™ Total Shoulder System - the first product Catalyst launched to the market. Catalyst continues to provide solutions that enable surgeons to deliver outcomes that outpace traditional total shoulder arthroplasty (TSA) solutions and this independent study introduced a new industry benchmark, showing that: Patients who underwent anatomic total shoulder arthroplasty (aTSA) with the Catalyst CSR system experienced exceptionally high patient satisfaction, little to no pain, significant functional improvements, and very low revision rates that are well below the average data published for similar aTSA implants. These clinical results highlight Catalyst's focus on anatomic precision and reproducible solutions that eliminate unnecessary complexity while enabling optimized outcomes. 'The data speaks volumes, but so does the growing enthusiasm we're seeing from the orthopedic community,' said Dr. Theodore Blaine, orthopedic surgeon. 'Catalyst has earned a reputation for smart shoulder arthroplasty solutions that align with how surgeons work and the results they expect – whether in hospitals or ASCs – and that's what makes it different.' Catalyst's commitment to surgeon engagement is just as strong as its product portfolio and pipeline. In addition to growing interest and presence at major orthopedic meetings, the company is strengthening its partnership with the American Shoulder and Elbow Surgeons (ASES) through sponsorship of the 2025 ASES Annual Meeting and the 2026 ASES Mentor & Mentee Meeting. These events provide a meaningful platform to connect with established thought leaders and rising surgical talent—reinforcing Catalyst's role as a company that listens, evolves, and leads and is the go-to partner for surgeons who demand better. This forward momentum underscores the company's focus – sustainable growth, surgeon-first mindset, and unmatched value for healthcare systems – which continues to resonate with the orthopedic community. Catalyst OrthoScience, based in Naples, Florida, is redefining shoulder replacement surgery. With a focus on less invasive techniques, fewer complications, and a more natural-feeling shoulder, Catalyst is breaking away from traditional approaches. Our total shoulder systems are engineered for precision and efficiency – preserving bone and soft tissue while enabling delivery of consistent, reproducible results. With a growing portfolio of issued and pending patents, Catalyst technology is available across the U.S. Learn more at and connect with us on LinkedIn.
Business Wire
an hour ago
- Business Wire
BostonGene Publishes Landmark Study Providing Clinical and Analytical Validation for Its Multimodal RNA and DNA Assay
WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced the publication of a pivotal study, ' Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort, ' in Communications Medicine, a high-impact journal in the Nature portfolio. The study underscores the BostonGene Tumor Portrait™ assay as a clinically robust, regulatory-grade platform that forms the foundation of BostonGene's AI-powered platform, purpose-built for precision oncology and designed to accelerate therapeutic development and enhance clinical data collection. 'Delivering clinically validated multimodal data from a single tumor sample—and interpreting it through an immune-focused, AI-enabled lens—represents a transformative advancement for oncology drug development.' The Tumor Portrait™ assay integrates DNA and RNA sequencing into a single end-to-end test, delivering a multimodal view of each tumor. Approved under CLIA, CAP and the New York State Department of Health, the platform enhances patient stratification, predictive biomarker discovery and clinical trial enrollment—all critical to reducing the risks associated with drug development and improving clinical trial success rates. The study details the implementation of highly stable clinical RNA-seq protocol, deployed in ready-to-use clinical settings and tested across more than 2,200 tumors, demonstrating high reproducibility, strong clinical actionability (98% of cases) and advanced detection of alterations, fusions, immune signatures, tumor microenvironment profiles and AI-based predictive classifications. 'Delivering clinically validated multimodal data from a single tumor sample—and interpreting it through an immune-focused, AI-enabled lens—represents a transformative advancement for oncology drug development,' said Alexander Bagaev, PhD, Chief Product Officer at BostonGene. 'By combining DNA and RNA sequencing in one assay, our platform enables deeper biological understanding of the tumor microenvironment and genetics, smarter patient selection and more confident, data-driven decisions throughout the drug development lifecycle. This validation sets a new benchmark for translational research and diagnostic innovation.' About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit
